top of page

Colombia's Invima and USP: Memorandum to Strenghthen the Quality of Medicine

Writer: Sharan MuruganSharan Murugan

Recently the National Institute for Food and Drug Surveillance - Invima and the United States Pharmacopeia - USP, celebrated the signing of a Memorandum of Understanding, which aims to formalize and strengthen relations and cooperation to Promote the quality of medicines.

Through this agreement, the cooperation ties between Invima and USP are strengthened, allowing the generation of spaces for dialogue and exchange of experiences based on good regulatory practices and strengthening the capacities of both institutions, in order to guarantee quality medicines. , safe and effective in our region.


Among the main agreements reached in this Memorandum of Understanding, the following stand out:

  • Provide technical and scientific assistance, and support that improves access to medicines with quality assurance.

  • Organize scientific events, seminars, conferences, meetings, workshops and symposiums. Promote internship programs, technical visits and training, including on-site modules.

  • Admit the participation of representatives of the Parties, as observers or ad hoc advisors in the scientific and expert committees or working groups.

  • Share experiences and information on the development of analytical methods. Jointly develop projects for the establishment, development and/or review of monographs and analytical methods, among others.

Click this LINK to know more about the Memorandum of Understanding that seeks to strengthen the quality of medicines.

Comments


I Sometimes Send Newsletters

Thanks for submitting!

  • LinkedIn
  • Facebook
  • Twitter
  • Instagram

DISCLAIMER

The views expressed in this publication do not necessarily reflect the views of any guidance of government, health authority, it's purely my understanding. This Blog/Web Site is made available by a regulatory professional, is for educational purposes only as well as to give you general information and a general understanding of the pharmaceutical regulations, and not to provide specific regulatory advice. By using this blog site you understand that there is no client relationship between you and the Blog/Web Site publisher. The Blog/Web Site should not be used as a substitute for competent pharma regulatory advice and you should discuss from an authenticated regulatory professional in your state.  We have made every reasonable effort to present accurate information on our website; however, we are not responsible for any of the results you experience while visiting our website and request to use official websites.

bottom of page